Aminobenzoic acids and derivatives
Apexbio Technology LLC Nafamostat 81525-10-2 10mg
Nafamostat (CAS 81525-10-2) is a small-molecule inhibitor targeting a broad spectrum of serine proteases including thrombin plasmin kallikrein and human trypsin It is designed to block protease-mediated hydrolysis reactions thereby regulating coagulation pathways and inflammation-related protease activity Nafamostat exerts its biological activity primarily through reversible binding to protease active sites inhibiting their enzymatic functions In biochemical assays Nafamostat demonstrates potent inhibitory activity with an IC50 value of approximately 1 10 nM against human trypsin Based on these pharmacological properties Nafamostat holds research potential in coagulation pathway studies inflammation-related protease research pancreatitis modeling and mechanistic investigations of blood coagulation disorders and inflammatory responses
Medchemexpress LLC NSC243928 mesylate | 59988-01-1 | 99.3% | 503.59 g/mol | C23H25N3O6S2 | 10MM 1ML
NSC243928 mesylate is a small-molecule LY6 (lymphocyte antigen 6) binder with reported antiproliferative and anticancer activity. It is available as a solid and as a ready-to-use 10 mM solution in DMSO for cell-based assays; published data report activity against several breast and ovarian cancer cell lines.
- Binds LY6 family proteins and inhibits cell growth.
- Reported IC50s: MDA-MB-231 5.683 μM; Hs-578-T 7.309 μM; BT-549 7.954 μM; OVCAR-8 4.167 μM.
- Available as solid and 10 mM solution in DMSO (1 mL).
- High purity: 99.33%.
- Molecular formula: C23H25N3O6S2; molecular weight: 503.59 g/mol.
- Soluble in DMSO to 10 mg/mL (≈19.86 mM) with warming.
- Store sealed, away from moisture; in solvent: -80°C up to 6 months, -20°C up to 1 month.
Medchemexpress LLC Gabexate (mesylate) | 56974-61-9 | 98.64% | 100 MG
Gabexate mesylate (FOY) is a competitive and non-antigenic synthetic inhibitor of trypsin-like serine proteinases. It inhibits human thrombin, urokinase, plasmin, and Factor Xa, and binds to human and bovine tryptase. It is used for pancreatitis and disseminated intravascular coagulation, and decreases proliferation rate in HepG2 cells in vitro.
- Anticoagulant effect by inhibiting the clotting activity of thrombin.
- Anti-inflammatory effect through the inhibition of NF-κB, proinflammatory cytokines, and nitric oxide.
- Therapeutic applications for pancreatitis and disseminated intravascular coagulation.
- Decreases the proliferation rate of HepG2 cells in a dose-dependent manner.
- Attenuates the development of mechanical allodynia induced by spinal nerve ligation (SNL) and inhibits the expression of pro-inflammatory cytokines after SNL in a rat model.
Medchemexpress LLC 4(5H)-thiazolone, 2-amino-5-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene] methanesulfonate | 139340-56-0 | MFCD00906463 | 99.7% | 428.57 g·mol⁻¹ | C19H28N2O5S2 | 10 MG
Darbufelone mesylate is a research-grade small molecule inhibitor that suppresses prostaglandin F2α and leukotriene B4 production by preferential inhibition of cyclooxygenase-2 (COX-2). Supplied as the mesylate salt for improved handling, it is intended for in vitro and in vivo research applications and is available as a solid or as a DMSO solution.
- Potent COX-2 inhibition (IC50 ≈ 0.19 μM)
- Dual inhibition of PGF2α and LTB4 production
- High purity suitable for research (≈99.7%)
- Soluble in DMSO (≈110 mg/mL), practically insoluble in water
- Available as 10 mg solid or 10 mM solution in DMSO
- Recommended storage sealed, away from moisture and light
Medchemexpress LLC Reboxetine mesylate | 98769-84-7 | 99.7% | C20H27NO6S | 50 MG
Reboxetine mesylate is a potent, selective, and specific noradrenaline reuptake inhibitor (NARI) primarily used for depression research. It effectively inhibits norepinephrine uptake with a Ki of 8 nM.
- Weak affinity for muscarinic, histaminergic H1, adrenergic α1, and dopaminergic D2 receptors.
- Prevents dexamethasone-induced decreases in cell viability and proliferation rate in SH-SY5Y cells (0.1 μM, 1 μM, 5 μM for 24 hours).
- Significantly decreases immobility time in mice depression models (30 mg/kg; i.p.).
Medchemexpress LLC Masitinib mesylate | 1048007-93-7 | MFCD12546334 | 100.0% | 594.75 g/mol | C29H34N6O4S2 | 5 MG
Masitinib mesylate is the mesylate salt form of masitinib, a small-molecule tyrosine kinase inhibitor. It is supplied as a high-purity analytical and research compound for in vitro and analytical applications and selectively inhibits c-Kit, PDGFR, and Src family kinases.
- Purity 99.98%.
- Molecular weight 594.75 g/mol.
- Molecular formula C29H34N6O4S2.
- Solubility in DMSO ≥ 30 mg/mL.
- Intended for research and analytical use.
- Available in a 5 mg pack size.
Apexbio Technology LLC Eprosartan Mesylate 144143-96-4 50mg
Eprosartan Mesylate is a small-molecule antagonist targeting the angiotensin II AT1 receptor It is designed to selectively inhibit the AT1 receptor subtype thereby modulating vasoconstriction and aldosterone secretion mechanisms in cardiovascular systems Eprosartan Mesylate exerts its biological activity primarily through competitive binding to AT1 receptors interfering with angiotensin II action In studies using rat and human adrenal cortical membranes Eprosartan Mesylate demonstrates inhibitory activity with IC50 values of approximately 9 2 nM and 3 9 nM respectively Based on these pharmacological properties Eprosartan Mesylate holds research potential in angiotensin II-mediated signal transduction pathways hypertension models and related cardiovascular diseases
Medchemexpress LLC Enasidenib mesylate | 1650550-25-6 | 99.7% | 569.48 | 1 ML
Enasidenib mesylate is a first-in-class, oral, potent, reversible, selective inhibitor of the IDH2 mutant enzymes. It is for research use only.
- Reverses effects of mutant IDH2 on DNA methylation.
- Induces differentiation and impairs self-renewal of IDH2-mutant leukemia cells.
- Improves survival in IDH2-mutant acute myeloid leukemia models.
- Remodels the epigenetic state of IDH2-mutant cells.
- Reduces 2-HG in vivo and restores differentiation.
Medchemexpress LLC Pefloxacin mesylate | 70458-95-6 | 99.7% | 1 G
Pefloxacin mesylate is a broad-spectrum antibiotic that blocks DNA replication by inhibiting DNA gyrase and DNA relaxation catalyzed by topoisomerase I. It exhibits antibacterial activity against various bacteria such as *Escherichia coli*, *Pseudomonas aeruginosa*, and *Bacteroides fragilis*. It has also shown activity against *Plasmodium yoelii* infection and can increase UVA-induced edema and immunosuppression, making it suitable for infection studies.
- Inhibits DNA replication by blocking DNA gyrase
- Inhibits DNA relaxation catalyzed by topoisomerase I (IC50 of 45 μg/mL)
- Exhibits broad-spectrum antibacterial activity
- Active against *Escherichia coli*, *Pseudomonas aeruginosa*, and *Bacteroides fragilis*
- Demonstrates activity against *Plasmodium yoelii* infection
- Increases UVA-induced edema and immunosuppression
- Suitable for infection studies
Medchemexpress LLC AZ7550 mesylate (AZ7550 trimesylate salt) | 2319837-99-3 | 98.7% | 773.90 g·mol⁻¹ | C30H43N7O11S3 | 10 MG
AZ7550 mesylate is the mesylate (trimesylate) salt of AZ7550, an active metabolite of AZD9291 that inhibits IGF1R (IC50 = 1.6 μM). It is provided as an analytical standard for biochemical and cellular research and is offered in small milligram packages and solution formats for assay use.
- Mesylate (trimesylate) salt form for improved handling and solubility.
- Reported IGF1R inhibitory activity with IC50 = 1.6 μM.
- High purity (~98.7%), suitable as an analytical standard.
- Molecular weight 773.90 g·mol⁻¹ and formula C30H43N7O11S3.
- Available in small quantities (5-100 mg) and as DMSO solutions for assay readiness.
Medchemexpress LLC Sns-314 mesylate | 1146618-41-8 | ≥98.0% | 25 MG
SNS-314 mesylate is the mesylate salt of SNS-314, a potent pan-Aurora kinase inhibitor active against Aurora A, B, and C used in preclinical research to investigate mitotic regulation and antineoplastic mechanisms.
- Potent inhibition of Aurora A, B, and C (IC50 ≈ 9, 31, and 6 nM)
- High purity: ≥98%
- Powder form, soluble in DMSO for screening and formulation
- Typical storage: -20 °C to preserve stability
- Provided as mesylate salt; formula C18H15ClN6OS2 • CH3SO3H, formula weight 527.0
Medchemexpress LLC Nafamostat mesylate (FUT-175) | 82956-11-4 | 99.9% | 100 MG
Nafamostat mesylate (FUT-175) is an anticoagulant and a synthetic serine protease inhibitor with demonstrated anticancer and antiviral effects. It induces apoptosis by up-regulating the expression of tumor necrosis factor receptor-1 (TNFR1) and is used in the development of treatments for pathological thickening of the arterial wall. This compound is intended for research use only.
- Anticoagulant and synthetic serine protease inhibitor
- Exhibits anticancer and antiviral effects
- Induces apoptosis by up-regulating TNFR1 expression
- Inhibits NF-κB activity
- Suppresses invasiveness in Panc-1 cells
- Demonstrates antiviral effects against Zika virus
- Inhibits neointimal formation after balloon injury
Medchemexpress LLC Gabexate mesylate (FOY) | 56974-61-9 | 98.6% | 50 MG
Gabexate mesylate (FOY) is a competitive and non-antigenic synthetic inhibitor of trypsin-like serine proteinases. It exerts an anticoagulant effect on the clotting activity of thrombin and has anti-inflammatory effects. It is used for pancreatitis and disseminated intravascular coagulation.
- Inhibits human thrombin, urokinase, plasmin, and Factor Xa
- Binds to human and bovine tryptase
- Attenuates mechanical allodynia in rats
- Decreases HepG2 cell proliferation rate
Medchemexpress LLC Nafamostat mesylate | 82956-11-4 | >99.8% | 1 ML
Nafamostat mesylate (FUT-175) is an anticoagulant and a synthetic serine protease inhibitor. It demonstrates anticancer and antivirus effects. It induces apoptosis by up-regulating the expression of tumor necrosis factor receptor-1 (TNFR1) and can be utilized in the development of treatments for the pathological thickening of the arterial wall.
- Anticoagulant
- Synthetic serine protease inhibitor
- Demonstrates anticancer effects
- Demonstrates antivirus effects
- Induces apoptosis by up-regulating the expression of tumor necrosis factor receptor-1 (TNFR1)
- Can be utilized in the development of treatments for pathological thickening of the arterial wall
Medchemexpress LLC Fgti-2734 (mesylate) | 2702297-24-1 | 99.7% | 10 MM 1 ML
FGTI-2734 mesylate is a RAS C-terminal mimetic dual farnesyl transferase (FT) and geranylgeranyl transferase-1 (GGT) inhibitor. It can prevent membrane localization of KRAS, which helps to solve KRAS resistance and thwart mutant KRAS patient-derived pancreatic tumors.
- Functions as a RAS C-terminal mimetic dual farnesyl transferase (FT) and geranylgeranyl transferase-1 (GGT) inhibitor.
- Exhibits IC50s of 250 nM for FT and 520 nM for GGT.
- Prevents membrane localization of KRAS.
- Addresses KRAS resistance.
- Thwarts mutant KRAS patient-derived pancreatic tumors.
- Induces apoptosis in mutant KRAS-dependent human cancer cells (in vitro).
- Inhibits protein prenylation of HDJ2, RAP1A, KRAS, and NRAS (in vitro).
- Inhibits tumor growth in mutant KRAS-dependent tumors (in vivo).